We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Non-Operative Management and Early Response Assessment in Rectal Cancer (NOM-ERA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03904043
Recruitment Status : Recruiting
First Posted : April 4, 2019
Last Update Posted : September 9, 2022
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:
The investigators' data from a phase I study of short course radiation therapy followed by chemotherapy showed 74% complete clinical response (cCR). Given the promising response rate, the investigators are evaluating short course radiation therapy (SCRT) followed by chemotherapy in a multi-institution phase II trial to validate the cCR rate of this treatment paradigm. SCRT has not been prospectively evaluated in non-operative management for patients with non-metastatic rectal adenocarcinoma.

Condition or disease Intervention/treatment Phase
Adenocarcinoma of the Lower Rectum Radiation: Radiation therapy Drug: FOLFOX regimen Other: Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire Procedure: Rectal biopsy samples Procedure: Blood for ctDNA Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 68 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Non-Operative Management and Early Response Assessment in Rectal Cancer
Actual Study Start Date : July 1, 2020
Estimated Primary Completion Date : June 30, 2024
Estimated Study Completion Date : December 31, 2025

Arm Intervention/treatment
Experimental: Radiation + FOLFOX
  • Pelvic radiotherapy 5GY x 5 fractions once daily
  • Radiation to extra-mesorectal node 7 Gy x 5 fractions once daily
  • FOLFOX should begin 2-4 weeks after completion of radiotherapy and will consist of FOLFOX x 8 cycles (16 weeks).

    • Oxaliplatin day 1 every 14 days
    • Leucovorin day 1 every 14 days. Levoleucovorin may be substituted if leucovorin is not available.
    • 5-FU bolus day 1 every 14 days
    • 5-FU infusion day 1 every 14 days over 46 hours
  • Alternatively CAPOX (capecitabine and oxaliplatin) may be given for 5 cycles over 15 weeks.
  • An optional simultaneous integrated boost of 30 Gy in 5 fractions to the primary tumor is permitted
Radiation: Radiation therapy
-Monday-Friday treatment is strongly recommended

Drug: FOLFOX regimen
-CAPOX can be given as alternative

Other: Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire
-Baseline, completion of chemotherapy (3-8 weeks after the end of chemotherapy), and 10 to 14 months after radiotherapy

Procedure: Rectal biopsy samples
-Multiple biopsy samples of the rectal tumor will be taken from the patient tumor prior to treatment initiation for genomic extraction. For patients at affiliate sites who do not have enough tissue from the diagnostic biopsy, a repeat pre-treatment biopsy is optional.

Procedure: Blood for ctDNA
-Prior to the start of treatment, Post radiation therapy labs (with standard of care (SOC) CBC/CMP prior to start of cycle 1 of chemotherapy), Day 1 of cycle 2 of chemotherapy (with SOC CBC/CMP), Completion of chemotherapy (3-8 weeks after the end of chemotherapy), months 3, 6, 9, 12, 16, 20, 24 until salvage surgery or 2 years from completion of chemotherapy (whichever is first)

Primary Outcome Measures :
  1. Clinical complete response rate [ Time Frame: Completion of treatment (estimated to be 22 weeks) ]

    -Criteria for clinical complete response:

    • No residual gross tumor at procto/sigmoidoscopy;, or only erythematous scar or ulcer
    • No palpable tumor on DRE
    • No radiographic evidence of tumor on MRI
    • No suspicious mesorectal lymph nodes on MRI
    • Negative biopsy from scar, ulcer, or former tumor site (if necessary according to surgeon's judgment)

Secondary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: 2 years ]
    • Criteria for progressive disease

      *Increase in the size of primary tumor by RECIST criteria

    • New metastatic disease

  2. Incidence of grade 3 or higher toxicity during treatment [ Time Frame: Completion of treatment (estimated to be 22 weeks) ]
    -The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.

  3. Incidence of post chemoradiotherapy grade 3 or higher toxicity [ Time Frame: 1 year ]
    -The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.

  4. Quality of anorectal function as measured by the FACT-C questionnaire [ Time Frame: 1 year (between 10-14 months post treatment start date) ]
    • Questionnaire with 5 sections (physical well-being, social/family well being, emotional well-being, functional well-being, and additional concerns)
    • Answers to the questions range from 0=not at all to 4=very much. The higher the total score the lower quality of life the person has

  5. Organ preservation rate [ Time Frame: 1 year ]
  6. Organ preservation rate [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of biopsy proven stage I-IIIB (cT1-3, N0-2a, M0) adenocarcinoma of the rectum; staging must also be based on multidisciplinary evaluation including MRI
  • Tumor ≤ 12 cm from anal verge as determined by MRI or endoscopy
  • Clinically detectable (MR, endoscopy, or DRE) tumor present
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • At least 18 years of age
  • Adequate bone marrow function defined as:

    • Absolute neutrophil count (ANC) > 1,500 cells/mm3
    • Hemoglobin> 8 g/dl
    • Platelets >100,000 cells/mm3
  • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
  • Able to understand and willing to sign an Institutional Review Board (IRB)-approved written informed consent document.

Exclusion Criteria

  • Prior radiation therapy, chemotherapy or extirpative surgery for rectal cancer.
  • Prior oxaliplatin or capecitabine use for any malignancy
  • No prior radiation therapy to the pelvis.
  • A history of other malignancy (except non-melanomatous skin cancers) with the exception of malignancies for which all treatment was completed at least 2 years before registration and the patient has no evidence of disease.
  • Currently receiving any investigational agents.
  • A history of allergic reaction attributed to compounds of similar chemical or biologic composition to capecitabine, 5FU, oxaliplatin, or leucovorin.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
  • Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 14 days of study entry.
  • Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective antiretroviral therapy (ART) according to Department of Health and Human Services (DHHS) treatment guidelines is recommended. HIV testing for patients without a history of HIV is not a protocol requirement.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03904043

Layout table for location contacts
Contact: Hyun Kim, M.D. 314-362-8502 kim.hyun@wustl.edu

Layout table for location information
United States, Colorado
University of Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Jeffrey Olsen, M.D.    719-365-6800      
Principal Investigator: Jeffrey Olsen, M.D.         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Christopher Hallemeier, M.D.       hallemeier.christopher@mayo.edu   
Principal Investigator: Christopher Hallemeier, M.D.         
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Hyun Kim, M.D.    314-362-8502    kim.hyun@wustl.edu   
Principal Investigator: Hyun Kim, M.D.         
Sub-Investigator: Sean Glasgow, M.D.         
Sub-Investigator: Kian-Huat Lim, M.D., Ph.D.         
Sub-Investigator: Matthew Mutch, M.D.         
Sub-Investigator: Matthew Silviera, M.D.         
Sub-Investigator: Rama Suresh, M.D.         
Sub-Investigator: Benjamin R Tan, M.D.         
Sub-Investigator: Nikolaos Trikalinos, M.D.         
Sub-Investigator: Paul Wise, M.D.         
Sub-Investigator: Esther Lu, Ph.D.         
Sub-Investigator: David DeNardo, Ph.D.         
Sub-Investigator: Radhika Smith, M.D.         
Sub-Investigator: Lauren Henke, M.D.         
Sub-Investigator: Shahed Badiyan, M.D.         
Sub-Investigator: Pamela Samson, M.D.         
Sub-Investigator: Carl DeSelm, M.D.         
Sub-Investigator: Olivia Aranha, M.D., Ph.D.         
Sub-Investigator: Patrick Grierson, M.D., Ph.D.         
United States, Vermont
University of Vermont Medical Center Recruiting
Burlington, Vermont, United States, 05401
Contact: Chris Anker, M.D.    802-847-3506    chris.anker@uvmhealth.org   
Principal Investigator: Chris Anker, M.D.         
Sub-Investigator: Steven Ades, M.D.         
Sub-Investigator: Maura Berry, M.D.         
Sub-Investigator: Marc Greenblatt, M.D.         
Sub-Investigator: Nataniel Lester-Coll, M.D.         
Sub-Investigator: Peter Cataldo, M.D.         
Sub-Investigator: Jesse Moore, M.D.         
Sub-Investigator: Krista Evans, M.D.         
Sponsors and Collaborators
Washington University School of Medicine
Layout table for investigator information
Principal Investigator: Hyun Kim, M.D. Washington University School of Medicine
Additional Information:
Layout table for additonal information
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT03904043    
Other Study ID Numbers: 201904029
First Posted: April 4, 2019    Key Record Dates
Last Update Posted: September 9, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Deidentified data will be shared with investigators who submit a sound proposal. Participants who opted out of data sharing in the informed consent will not be included.
Time Frame: Up to 5 years after completion of the study
Access Criteria: Proposals should be directed to kim.hyun@wustl.edu. To gain access, data requestors will need to sign a data access agreement and provide proof of appropriate regulatory approvals as necessary.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Rectal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases